GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, today announced the publication of a peer ...

Oncology, and Biosecurity Amid Strategic Program Developments ATLANTA, GA - April 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc.

GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb ...

D. Boral Capital lowered the firm’s price target on GeoVax Labs (GOVX) to $14 from $18 and keeps a Buy rating on the shares.

Despite the PNG award termination, GeoVax anticipates a milestone-rich 2025 across its portfolio. The Company will continue to engage with government and industry partners, pursue clinical trial ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on GeoVax Labs (GOVX – Research Report), Tango Therapeutics (TNGX – Research Repo ...

On April 11, 2025, GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines with a market capitalization of $14.39 million, was instructed to halt all ...

On April 11, 2025, GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines with a market capitalization of $14.39 million, was instructed to halt all ...

U.S. stock futures were volatile on Tuesday following a two-day advance. Futures of major benchmark indices were mixed in ...